New Alzheimer’s Drug ANAVEX 2-73: A Phase 2a Study, Clinical Safety, Tolerability and Maximum Tolerated Dose finding in mild-to-moderate Alzheimer’s Patients. January 11, 2016
Novel Anti-Seizure Compound ANAVEX 2-73 a Sigma-1 Receptor Agonist in Multiple Seizure Models. December 11, 2015
Independent Research Describes ANAVEX 3-71 as Potent Cognitive Enhancer in Alzheimer’s Disease Models November 30, 2015
New Exploratory Alzheimer’s Drug ANAVEX 2-73: Assessment of Safety and Cognitive Performance in a Phase 2a Study in mild-to-moderate Alzheimer’s Patients. November 27, 2015
